The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2.
about
Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancerThe androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancerQuantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosisCoexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancerRelationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancerAlterations of the extracellular matrix of lung during zinc deficiencyRelationship between parameters from virtual touch tissue quantification (VTQ) imaging with clinicopathologic prognostic factors in women with invasive ductal breast cancerGene regulation, modulation, and their applications in gene expression data analysisStrategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.Apoptin-induced cell death is modulated by Bcl-2 family members and is Apaf-1 dependent.Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer.Studies of apoptosis in breast cancer.How apoptosis is regulated, and what goes wrong in cancerVaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection.BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatmentRole of steroid hormones and growth factors in breast cancer.TP53 status and response to treatment in breast cancersBikDDA, a mutant of Bik with longer half-life expression protein, can be a novel therapeutic gene for triple-negative breast cancer.Trastuzumab-based combination therapy for breast cancer.The role of surrogate markers in the clinical development of antiretroviral therapy: a model for early evaluation of targeted cancer drugs.Expression of a-Tocopherol-Associated protein (TAP) is associated with clinical outcome in breast cancer patients.The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer.Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease.Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer.DNA damage induces down-regulation of UDP-glucose ceramide glucosyltransferase, increases ceramide levels and triggers apoptosis in p53-deficient cancer cells.Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer.Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome.Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women.Targeting the B-cell lymphoma/leukemia 2 family in cancer.A subset of breast invasive ductal carcinoma with distinctive cytomorphology, aggressive clinical behavior, and unique immunologic profiles.Impact of patient age on the outcome of primary breast carcinoma.Combining Pathway Identification and Breast Cancer Survival Prediction via Screening-Network Methods.
P2860
Q24642830-E8458B8C-733E-441B-AB7B-8C3CCDB2B2D7Q24646770-819B0A5D-8E15-4D66-9709-B55437D2AF61Q24646799-53A34036-AA35-4986-ABFA-AC80770B37DAQ24803894-3B4359EB-401A-4164-88D3-823121BA92D7Q28364208-FC8762F0-D2AB-4387-8F92-C114C67BD4C4Q28583361-DD475267-3AC1-4663-80A7-4980CE5EED4CQ30426167-B3F8EC68-EDB7-4FE8-93F5-5026A38ED07AQ30614377-5422DBDB-B97B-40D6-9D5A-AEE6F2618D27Q30857631-DADF2727-38EA-4FEC-AC44-CF67E9D9AB94Q33227197-367C5A09-0184-403D-98F8-C3A9DE9172B3Q33281956-6B5D7499-87AC-4887-A4A7-C6E674679057Q33378965-62288E50-C82A-4237-9D67-FEC61B34AF15Q33793142-A9846A47-0229-4144-87A7-D89550592680Q33806008-25293E1A-BC56-4F56-887E-F76812012BB5Q34290061-CE081498-668C-4D01-A838-59D10F2EB582Q34553600-5A9A0AEC-E096-4EC3-83DA-638983A350E4Q34632169-3055BE7C-2E8E-4ABE-9570-1750CF76B015Q35023097-C8D75249-4509-466B-846E-688D6CA55EE1Q35043933-D0327891-0DDC-4AF0-AEF4-F44728983CFEQ35122880-DA19B55F-14D0-4550-85CD-1BC555F05240Q35609686-84E0EC0D-61A0-40AA-80DA-17BA54F67FF7Q35740281-71FEEBEB-4312-419F-95A8-8DA332F57B65Q35868074-C188482D-CD31-4373-BEA4-480B57A5635EQ36430748-BD933DB5-276E-4F36-8335-0D6EA075F5BEQ36615272-818C98F6-BFB4-40F5-951F-854DBAAEA2D1Q36648420-9E93DEA7-D5B3-4F81-BEB7-D364FB5F9F02Q36734546-6D22A4E4-B69E-4AC5-AB33-6E4930431A36Q37277274-D6F7C43A-D655-4AF6-9738-28A7A9148451Q37354971-C555D73A-978B-4111-A40E-2CD1C88DBB8BQ37356185-2C8EAD88-97A3-46A6-8AF5-A5C6B015CF63Q38014808-F32A6625-8048-4E5D-90F0-07EE8C85D1CFQ44178439-E3199FB4-3680-4D45-B2EC-5B655E4659DCQ53671085-7E210FEB-5B52-4EC7-BA68-FF13B622D3AEQ55369745-AE502159-1663-45C3-BD1C-D5F8DFC5EB7F
P2860
The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The contribution of molecular ...... ature on HER-2, p53 and BCL-2.
@ast
The contribution of molecular ...... ature on HER-2, p53 and BCL-2.
@en
The contribution of molecular ...... ature on HER-2, p53 and BCL-2.
@nl
type
label
The contribution of molecular ...... ature on HER-2, p53 and BCL-2.
@ast
The contribution of molecular ...... ature on HER-2, p53 and BCL-2.
@en
The contribution of molecular ...... ature on HER-2, p53 and BCL-2.
@nl
prefLabel
The contribution of molecular ...... ature on HER-2, p53 and BCL-2.
@ast
The contribution of molecular ...... ature on HER-2, p53 and BCL-2.
@en
The contribution of molecular ...... ature on HER-2, p53 and BCL-2.
@nl
P356
P1433
P1476
The contribution of molecular ...... ature on HER-2, p53 and BCL-2.
@en
P2093
P304
P356
10.1023/A:1008390429428
P577
2000-06-01T00:00:00Z